HC Wainwright reissued their buy rating on shares of Talaris Therapeutics (NASDAQ:TALS – Get Rating) in a research note published on Monday morning, Benzinga reports. They currently have a $12.00 target price on the stock. HC Wainwright also issued estimates for Talaris Therapeutics' Q4 2022 earnings at ($0.50) EPS, Q2 2023 earnings at ($0.55) EPS, Q3 2023 earnings at ($0.51) EPS and FY2023 earnings at ($2.07) EPS.
Talaris Therapeutics Stock Up 2.3 %
NASDAQ TALS opened at $1.77 on Monday. The company has a market cap of $73.85 million, a price-to-earnings ratio of -1.07 and a beta of 2.36. Talaris Therapeutics has a 52 week low of $0.89 and a 52 week high of $10.56. The business has a 50 day moving average price of $1.27 and a 200-day moving average price of $2.37.
Get
Talaris Therapeutics alerts:
Talaris Therapeutics (NASDAQ:TALS – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04). On average, equities research analysts anticipate that Talaris Therapeutics will post -1.87 earnings per share for the current year.
Institutional Investors Weigh In On Talaris Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of TALS. Two Sigma Investments LP purchased a new position in shares of Talaris Therapeutics during the third quarter valued at approximately $93,000. BNP Paribas Arbitrage SNC purchased a new position in shares of Talaris Therapeutics during the third quarter valued at approximately $64,000. Virtu Financial LLC purchased a new position in shares of Talaris Therapeutics during the second quarter valued at approximately $56,000. Commonwealth Equity Services LLC purchased a new position in shares of Talaris Therapeutics during the third quarter valued at approximately $34,000. Finally, Values First Advisors Inc. boosted its position in shares of Talaris Therapeutics by 29.9% during the fourth quarter. Values First Advisors Inc. now owns 39,891 shares of the company's stock valued at $41,000 after buying an additional 9,176 shares during the last quarter. Institutional investors own 65.43% of the company's stock.
Talaris Therapeutics Company Profile
(Get Rating)
Talaris Therapeutics, Inc operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders.
Featured Articles
- Get a free copy of the StockNews.com research report on Talaris Therapeutics (TALS)
- Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
- Mullen Automotive Stock Gains Momentum On Positive News
- Harley-Davidson Inc. Stock, Is It Time To Buy?
- The Bottom Is In For Meta Platforms, Volatility Is Not Over
- Analyzing Alaska Air's Recent Earnings
Receive News & Ratings for Talaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Talaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
HC Wainwright重新发布了对以下股票的买入评级塔拉里斯治疗公司(纳斯达克:TALS-GET评级)在周一上午发布的一份研究报告中,本辛加报道。他们目前对该股的目标价为12.00美元。HC Wainwright还发布了对Talaris治疗公司2022年第四季度每股收益(0.50美元)、2023年第二季度每股收益(0.55美元)、2023年第三季度每股收益(0.51美元)和2023财年每股收益(2.07美元)的估计。
Talaris治疗公司股票上涨2.3%
周一,纳斯达克股价开盘报1.77美元。该公司市值为7385万美元,市盈率为-1.07倍,贝塔系数为2.36。Talaris Treeutics的52周低点为0.89美元,52周高点为10.56美元。该业务的50日移动均线价格为1.27美元,200日移动均线价格为2.37美元。
到达
塔拉里斯治疗公司警报:
塔拉里斯治疗公司(纳斯达克代码:TALS-GET Rating)最近一次发布季度收益数据是在11月10日星期四。该公司公布了该季度每股收益(0.46美元),低于普遍预期的(0.42美元)和(0.04美元)。平均而言,股票研究分析师预计Talaris治疗公司本年度的每股收益将达到1.87美元。
机构投资者看好Talaris Treeutics
几家对冲基金和其他机构投资者最近调整了他们持有的TAL。Two Sigma Investments LP在第三季度购买了Talaris治疗公司新的股票头寸,价值约93,000美元。法国巴黎银行套利SNC在第三季度购买了Talaris治疗公司新的股票头寸,价值约6.4万美元。Virtu Financial LLC在第二季度购买了Talaris治疗公司新的股票头寸,价值约5.6万美元。英联邦股权服务公司在第三季度购买了Talaris治疗公司新的股票头寸,价值约3.4万美元。最后,Values First Advisors Inc.在第四季度将其在Talaris Treeutics的股票头寸提高了29.9%。Values First Advisors Inc.现在持有39,891股该公司股票,价值41,000美元,该公司在上个季度又购买了9,176股。机构投资者持有该公司65.43%的股份。
Talaris治疗公司简介
(获取评级)
Talaris治疗公司在美国作为一家临床晚期细胞治疗公司运营。该公司致力于开发异基因造血干细胞移植的方法,以改变实体器官移植和严重的自身免疫性疾病以及严重的非恶性血液、免疫和代谢疾病的护理标准。
专题文章
- 免费获取StockNews.com关于Talaris治疗(TALS)的研究报告
- 凯西·伍兹的方舟创新ETF将在2023年反弹?
- 马伦汽车公司股票因利好消息而上涨
- 哈雷-戴维森公司的股票,是时候买入了吗?
- Meta平台的底部已经到了,波动性还没有结束
- 阿拉斯加航空公司近期收益分析
接受Talaris治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Talaris治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。